Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. JAMA.1993;269:3015-3023.
Avins AL, Browner WS. Lowering risk without lowering cholesterol: implications for national
cholesterol policy. Ann Intern Med.1996;125:502-506.
Davey-Smith G, Egger M. Who benefits from medical interventions? BMJ.1994;308:72-74.
Goldman L, Gordon DJ, Rifkind BM.
et al. Cost and health implications of cholesterol lowering. Circulation.1992;85:1960-1968.
McIsaac WJ, Naylor CD, Basinski A. Mismatch of coronary risk and treatment intensity under the National
Cholesterol Education Program guidelines. J Gen Intern Med.1991;6:518-523.
Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation.1991;83:356-362.
Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med.1996;124:518-531.
McDowell A, Engle A, Massey JT, Maurer K. Plan and Operation of the Second National Health and Nutrition
Examination Survey 1976-1980. Washington, DC: US Government Printing Office; 1981.
Johnson CL, Rifkind BM, Sempos CT.
et al. Declining serum total cholesterol levels among US adults: the National
Health and Nutrition Examination Surveys. JAMA.1993;269:3002-3008.
US Bureau of the Census. United States Population Estimates, by Age, Sex, Race, and Hispanic
Origin, 1996 to 2000. Washington, DC: US Bureau of the Census; 1996.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation
tool in clinical medicine. Clin Chem.1993;39:561-577.
Swets JA. Measuring the accuracy of diagnostic systems. Science.1988;240:1285-1293.
StataCorp. Stata Statistical Software: Release 5.0. College Station, Tex: Stata Corp; 1996.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic
(ROC) curve. Radiology.1982;143:29-36.
Mossman D. Resampling techniques in the analysis of non-binormal ROC data. Med Decis Making.1995;15:358-366.
Jacobs DR, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA. High density lipoprotein cholesterol as a predictor of cardiovascular
disease mortality in men and women: the follow-up study of the Lipid Research
Clinics Prevalence Study. Am J Epidemiol.1990;131:32-47.
Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Ann Epidemiol.1992;2:161-176.
Shepherd J, Cobbe SM, Ford I.
et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia:
West of Scotland Coronary Prevention Study Group. N Engl J Med.1995;333:1301-1307.
Pedersen TR, Kjekshus J, Olsson A.
et al. Scandinavian Simvistatin Study (4S). Lancet.1994;344:1765-1768.
Sacks FM, Pfeffer MA, Moye LA.
et al. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
Forrester JS, Shah PK. Using serum cholesterol as a screening test for preventing coronary
heart disease: the five fundamental flaws of the American College of Physicians
guidelines. Am J Cardiol.1997;79:790-792.
Glick H, Heyse JF, Thompson D, Epstein RS, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering
treatment. Int J Technol Assess Health Care.1992;8:719-734.
Perkins KA. Family history of coronary heart disease: is it an independent risk
factor? Am J Epidemiol.1986;124:182-194.